RESULTS AND DISCUSSION
|
|
- Shannon Glenn
- 5 years ago
- Views:
Transcription
1 RESULTS AND DISCUSSION 203
2 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire and interviews. A pilot study was conducted and accordingly the interview pattern and questionnaire have been suitably modified to extract more information. The collected data are inline with the overall pharmaceutical industries present status and leads to the future growth. The graphical representation followed by the statistical analysis. Each hypothesis has been tested using the statistical tools like Chi Square, Bi Nomial, Descriptive and Spearman s correlation coefficient tool and the inference have been drawn by doing the hypothesis testing and validation. The senior people of the top 30 Indian pharmaceutical industries and people associated have been questioned formally and informally and the data collected and compiled and tabulated and made the graphical representation. The collected data compiled and presented in tabular section along with the discussion for reference. 204
3 Indian pharmaceutical companies have survived on the strength of reverse engineering where by taking the process patent of patented drugs and by doing the improvement in the chemistry and engineering, has made a niche in the generic business. Table: 4.1 Indian pharmaceutical companies are going for products already /getting off patented in future. Sr. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited Yes 1 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited Yes 1 8 Alkem Laboratories Limited Yes 1 9 Abbott (India) Limited Yes 1 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited Yes 1 13 Sanofi Aventis (India) Limited Yes 1 14 Alembic Limited Yes 1 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited Yes 1 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited Yes 1 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited Yes 1 30 Merck (India) Limited Yes 1 Yes 1 and No
4 Table: 4.2 Indian pharmaceutical companies are opting for the large generic volume ( ). Sr. No Title Details Num 1 Ranbaxy Laboratories 78% 3 2 Cipla Limited 93% 1 3 GlaxoSmithKline (India) Limited 100% 1 4 Piramal Healthcare Limited 92% 1 5 Zydus Cadila Limited 84% 3 6 Sun Pharmaceutical Industries Limited 82% 3 7 Pfizer (India) Limited 100% 1 8 Alkem Laboratories Limited 96% 1 9 Abbott (India) Limited 100% 1 10 Lupin Laboratories Limited 84% 3 11 Dr. Reddy s Laboratories Limited 60% 4 12 Aristo Pharma Limited 100% 1 13 Sanofi Aventis (India) Limited 100% 1 14 Alembic Limited 91% 1 15 Novartis (India) Limited 95% 1 16 Mankind Pharma Limited 100% 1 17 Torrent Pharmaceuticals Limited 91% 1 18 Intas Pharmaceuticals limited 92% 1 19 Wockhardt Limited 81% 3 20 Micro Labs Limited 94% 1 21 Emcure Pharmaceuticals Limited 90% 1 22 FDC Limited 96% 1 23 Unichem Laboratories Limited 91% 1 24 Macleods Pharmaceuticals Limited 98% 1 25 USV Limited 82% 3 26 Ipca Laboratories Limited 87% 2 27 Glenmark Pharmaceuticals Limited 84% 3 28 Cadila Pharmaceuticals Limited 92% 1 29 Elder Pharmaceuticals Limited 95% 1 30 Merck (India) Limited 95% 1 V2 Very High Volume 90% & above 1 High Volume 85-90% 2 Low Volume 70-85% 3 Very Low Volume 70% & below 4 206
5 Indian pharmaceutical companies are going for products already / getting off patented in the near future. No Yes 100% Fig. 4.1 It is clear that all Indian pharmaceutical companies are going for the off patented drugs and presently it is a major constituent of their portfolio. Indian pharmaceutical companies are opting for large generic volume. 3% 24% 3% 70% 90% & above 85-90% 70-85% 70% & Below Fig
6 Pharmaceuticals can be divided into two parts: 1. The one which is considered as bulk drugs (Active Pharmaceutical Ingredients). This is not considered as a part of generics. 2. All the dosage form like oral solid, liquid and injectable will fall under the head of generics and have been considered. The generic market consists of branded formulation, generic formulation and institutional tenders. Exclusions, 1. Contract research 2. In licensing and out licensing deals 3. The milestone payment against the research development With the data shown in Fig. 4.2 it is clear that Indian pharmaceutical companies are going for the products already off patented and are going to be off patented in the near future. The pie chart indicates that 70% Indian pharmaceutical companies have the generic volume as more than 90% of their total volume. More than 30% of global generic volume is presently catered by Indian pharmaceutical companies. Any drug which has an annual sales of more than Rs.4,500 crore (US$ 1 billion) globally is considered a block buster drug. The patent is given for 20 years but the patent holder tries to increase the patent by adding novelty and tries to extend its validity. The few Indian pharma companies have tried to challenge the process patent of block buster drug (Table 4.3). 208
7 Table: 4.3 Indian pharmaceutical companies to challenge the process patent of Block buster drugs. Sr. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited No 2 19 Wockhardt Limited No 2 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited No 2 26 Ipca Laboratories Limited No 2 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited No 2 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
8 Table: 4.4 Indian pharmaceutical companies already challenged block buster drugs for Exclusive Marketing Rights (EMR). Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited No 2 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited No 2 5 Zydus Cadila Limited No 2 6 Sun Pharmaceutical Industries Limited No 2 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited No 2 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited No 2 19 Wockhardt Limited No 2 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited No 2 26 Ipca Laboratories Limited No 2 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited No 2 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No- 2 In order to market a generic drug in United States of America (USA), a company needs to file Abbreviated New Drug Application (ANDA). When filing an Abbreviated New Drug Application (ANDA), the company is required to certify that its product is not infringing any patent rights or the patent is invalid (para IV certification). If the company successfully proves that the patent in invalid of if it is 210
9 the first one to get approval for the generic version, it gets market exclusively for 180 days during which no other generic company is permitted to enter the market. This exclusivity is available under the Drug Price Competition and Patent Restoration Act of 1984 or better known as the Hatch-Waxman Act. A successful first to file para IV Abbreviated New Drug Application (ANDA) can bring immense profits to the company. Dr. Reddy s, the first Indian company to get the 180 days exclusivity for marketing fluoxetine 40 mg in August 2001, saw its sale of generics increasing from Rs.30.4 crores in to Rs.406 crores in the year Sale of fluoxetine 40 mg contributed 81% of total generics sales and about half of Dr. Reddy s operating profit in the financial year Patent litigation under para IV is highly risky also as a failure means a loss of several years of hard work and huge legal expenses. Companies also engage in developing non-infringing processes for Abbreviated New Drug Application (ANDA) filing. A Matrix laboratory was the first Indian company to develop a non-infringing process for manufacturing citaopram. The company was able to reap huge benefits with its sales of the product were Rs.560 crore till the year Another commercially successful example is the cefotaxime process developed by Lupin. Since 2002, both Ranbaxy and Dr. Reddy s Laboratory have taken steps towards registering themselves as the first movers in the generics for a number of drugs. Data obtained from the Food and Drug Administration (FDA) shows that while Ranbaxy has been able to obtain approvals for 22 drugs as the first time generics between year 2002 and 2005, Dr. Redyy s has been able to obtain similar approvals for 8 drugs. More recently Glenmark got first to file status for three drugs having combined revenue of over Rs.9,000 crore (US $2 billion). The three drugs are Zetia (Ezetimibe) with annual sales of Rs.6,750 (US $1.5 billion) in the United States of America (USA) in 2008, Tarka (Trandolapril + Verapamil) with annual sales of Rs.324 crores (US $72 million) and Cultivate (Fluticasone lotion) with annual sales of Rs.166 crores (US $37 million). 211
10 Only few companies, particularly Ranbaxy and Dr. Reddy s had Abbreviated New Drug Applications (ANDAs) in their name till recently. Companies like Cipla had Abbreviated New Drug Applications (ANDAs) in the names of their marketing partners in the United States of America (USA). This situation has changed dramatically in the recent times and more companies are engaged in securing Abbreviated New Drug Applications (ANDAs). From 161 Abbreviated New Drug Application (ANDAs) filed by four companies Ranbaxy, Dr. Reddy s, Wockhardt and Lupin in the last quarter of year 2003, the number has gone up to 701 Abbreviated New Drug Applications (ANDAs) files by 17 companies by the second quarter of year Abbreviated New Drug Application (ANDA) approvals held by Indian firms as percentage of total approvals have gone up sharply from 7% in year 2001 to 21% in year 2006 to 30% in year 2008 and to 35% in year 2009 till 23 rd February. Indian pharmaceutical companies already challenged Block Buster drugs for Exclusive Marketing Rights (EMR) 10% No Yes 90% Fig. 4.3 It is clear from the Fig. 4.3 that three Indian pharma companies have already challenged the process patent and have won the Exclusive Marketing Rights (EMR). Ranbaxy, Dr. Reddy s and Glenmark have so far challenged the blockbuster drugs of multinational to get Exclusive Market Rights. 212
11 Fig. 4.4 With the research it is clear that 27% of Indian pharmaceutical company s intent to challenge the process patent of block buster drug from Fig 4.4. Pharmaceutical companies like Cipla, Piramal Healthcare, Zydus Cadila, Lupin Laboratories and Sun Pharmaceuticals are also having the strategy for challenging the process patent of the block buster drugs. India has a good scientific base and has reasonably good academic institutes in addition it has large English speaking literate population. The Research & Development (R&D) is a huge cost in west. On an average a drug discovery takes 12 to 15 years with more than Rs.5,850 crores (US$ 1.3 billion) investment. Western companies are looking for Research & Development (R&D) outsourcing from India to reduce this spending. 213
12 Table: 4.5 Indian pharmaceutical companies to build independent Research & Development (R&D) infrastructure. Sr. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited No 2 19 Wockhardt Limited No 2 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited No 2 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
13 Table: 4.6 Indian pharmaceutical companies building up Research & Development (R&D) infrastructure for research contract collaboration. Sr. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited No 2 19 Wockhardt Limited No 2 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited No 2 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
14 Table: 4.7 Indian pharmaceutical companies Research & Development (R&D) in terms of scientist s strength as in the year Sr. Title Details Num 1 Ranbaxy Laboratories Cipla Limited GlaxoSmithKline (India) Limited Piramal Healthcare Limited Zydus Cadila Limited Sun Pharmaceutical Industries Limited Pfizer (India) Limited Alkem Laboratories Limited Abbott (India) Limited Lupin Laboratories Limited Dr. Reddy s Laboratories Limited Aristo Pharma Limited Sanofi Aventis (India) Limited Alembic Limited Novartis (India) Limited Mankind Pharma Limited Torrent Pharmaceuticals Limited Intas Pharmaceuticals limited Wockhardt Limited Micro Labs Limited Emcure Pharmaceuticals Limited FDC Limited Unichem Laboratories Limited Macleods Pharmaceuticals Limited USV Limited Ipca Laboratories Limited Glenmark Pharmaceuticals Limited Cadila Pharmaceuticals Limited Elder Pharmaceuticals Limited Merck (India) Limited V3 Very High Volume 600 < 1 High Volume Low Volume Very Low Volume <
15 Fig. 4.5 It has been found that out of 30 Indian pharmaceutical companies, 11 companies that is 37% (Fig 4.5) are building independent Research & Development (R&D) infrastructure (Table 4.5 and 4.6) and have deployed sizeable number of scientists (Table 4.7) to meet this collaborative research requirement. The Research & Development has been given the status of a profit centre and is a money churner. 217
16 Indian pharmaceutical companies Research & Development in terms of Scientist strength 50% 7% 16% 27% 600 < <200 Fig. 4.6 The Fig. 4.6 above indicates that 50% of the Indian pharmaceutical companies have Research & Development scientist in the range of and 27% in the range of numbers of scientists, in order to make the strong presence in the new development and technologies. 218
17 Table: 4.8 Indian pharmaceutical companies creating the facilities for Active Pharmaceutical Ingredients (API) form to meet the United States Food and Drug Administration (USFDA) guidelines. Sr. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
18 Table: 4.9 Indian pharmaceutical companies creating facilities for Active Pharmaceutical Ingredients (API) form to meet the Medicines and Healthcare Products Regulatory Agency (MHRA) guidelines. Sr. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
19 Table: 4.10 Indian pharmaceutical companies creating facilities for Active Pharmaceutical Ingredients (API) form to meet the Medicines Control Council (MCC) guidelines. Sr. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited Yes 1 25 USV Limited No 2 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
20 Table: 4.11 Indian pharmaceutical companies creating facilities for Active Pharmaceutical Ingredients (API) form to meet the Therapeutic Goods Administration of Australia (TGA) guidelines. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
21 Fig. 4.7 Looking into the strengths, competency and the capability to deliver consistent results, Indian pharmaceutical companies have developed a good recognition world wide and commands greater acceptability. It is clear from the research Fig. 4.7 that, 63.33% of Indian pharmaceutical companies have already built up the manufacturing facility for Active Pharmaceutical Ingredients (APIs) to meet the regulatory approval of United States Food and Drug Application (USFDA) (Table 4.7). 223
22 Fig. 4.8 It is clear from Fig. 4.8 that 66.67% Indian pharmaceutical companies have already built up the manufacturing facility for Active Pharmaceutical Ingredients (APIs) to meet the regulatory approval of Medicines and Healthcare Products Regulatory Agency (MHRA). 224
23 Fig. 4.9 It is clear from Fig. 4.9 that 66.67% Indian pharmaceutical companies have already built up the manufacturing facility for Active Pharmaceutical Ingredients (APIs) to meet the regulatory approval of Medicines Control Council (MCC). The companies like Cadila Pharma, Unichem Labs, and Ipca Laboratories are in the race for creating manufacturing facilities of Active Pharmaceuticals Ingredients (API) to meet the regulatory approval of Medicines Control Council (MCC) (South Africa). 225
24 Fig It is clear from Fig that 63.33% Indian pharmaceutical companies have already built up the manufacturing facility for Active Pharmaceutical Ingredients (APIs) to meet the regulatory approval of Therapeutic Goods Administration of Australia (TGA). The companies like Cadila Pharma, Sun Pharmaceuticals, Micro Labs, Unichem Labs and Ipca Laboratories have manufacturing facilities for Active Pharmaceutical Ingredients (API) to meet the regulatory approval of Therapeutic Goods Administration of Australia (TGA) for their respective bulk drugs. 226
25 Table: 4.12 Indian pharmaceutical companies creating facilities for dosage form to meet the United States Food and Drug Administration (USFDA) guidelines. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited Yes 1 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited No 2 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
26 Table: 4.13 Indian pharmaceutical companies creating facilities for dosage form to meet the Medicines and Health care Products Regulatory Agency (MHRA) guidelines. Sr.No. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited Yes 1 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited Yes 1 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
27 Table: 4.14 Indian pharmaceutical companies creating facilities for dosage form to meet the Medicines Control Council (MCC) guidelines. Sr.No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited Yes 1 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited Yes 1 25 USV Limited No 2 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
28 Table: 4.15 Indian pharmaceutical companies creating facilities for dosage form to meet the Therapeutic Goods Administration of Australia (TGA) guidelines. Sr. No. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited Yes 1 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
29 Fig It is clear from Fig that majority of Indian pharmaceutical companies have built up their manufacturing facility for dosage to meet the regulatory approval of United States Food and Drug Application (USFDA). The list of Indian pharmaceutical companies for dosage form manufacturing facility includes, Cipla Limited, Sanofi Aventis, Ranbaxy Laboratories, Piramal Healthcare, Sun Pharmaceutical and few more. India has taken major lead in manufacturing and today outside United States of America (USA) maximum number of United States Food and Drug Administration (USFDA) approved plants are in India. 231
30 Fig It is clear from Fig that 73.33% of the Indian pharmaceutical companies have already built up their manufacturing facility for dosage to meet the regulatory approval of Medicines and Healthcare Products Regulatory Agency (MHRA). 232
31 Fig It is clear from the Fig.4.13 that 66.67% of the Indian pharmaceutical companies have already built up their manufacturing facility for dosage to meet the regulatory approval of Medicines Control Council (MCC). 233
32 Table: 4.16 Indian pharmaceutical companies tie up with Multinational companies (MNCs) for the contract manufacturing for dosage form. Sr.No. Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited No 2 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited Yes 1 30 Merck (India) Limited No 2 Yes 1 and No
33 Table: 4.17 Indian pharmaceutical companies having the manufacturing sites in the developed country for the contract manufacturing of dosage form. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited No 2 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited No 2 26 Ipca Laboratories Limited No 2 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
34 Fig From the Fig above, it is clear that 63.33% Indian pharmaceutical companies are tying up with multinational firms for contract manufacturing of dosage form in India. Indian pharmaceutical companies have started exploring their business in the new era of the contract manufacturing opportunities for the reputed multinational companies of the world in order to acquire more quanta of the business. Indian pharmaceutical companies have gone for major tie ups with multinational companies. Many of the Indian pharmaceutical legends like Ranbaxy, Dr. Reddy s Laboratories, Glenmark Pharmaceuticals and Zydus Cadila have built up their manufacturing plants for dosage form in India as well as in the developed countries in order to cater to contract manufacturing strategy. 236
35 Fig From the Fig.4.15 above, it is clear that 40% of the Indian pharmaceutical companies have manufacturing facilities for their dosage form in the developed countries of the world. 237
36 Table: 4.18 Indian pharmaceutical companies having turnover in Rs. crores for the Financial Year Sr.No. Title Turnover Num 1 Ranbaxy Laboratories 5, Cipla Limited 4, GlaxoSmithKline (India) Limited 1, Piramal Healthcare Limited 2, Zydus Cadila Limited 2, Sun Pharmaceutical Industries Limited 3, Pfizer (India) Limited 1, Alkem Laboratories Limited 1, Abbott (India) Limited 1, Lupin Laboratories Limited 2, Dr. Reddy s Laboratories Limited 4, Aristo Pharma Limited Sanofi Aventis (India) Limited Alembic Limited 1, Novartis (India) Limited Mankind Pharma Limited Torrent Pharmaceuticals Limited 1, Intas Pharmaceuticals limited 1, Wockhardt Limited 2, Micro Labs Limited Emcure Pharmaceuticals Limited 1, FDC Limited Unichem Laboratories Limited Macleods Pharmaceuticals Limited USV Limited Ipca Laboratories Limited 1, Glenmark Pharmaceuticals Limited 2, Cadila Pharmaceuticals Limited Elder Pharmaceuticals Limited Merck (India) Limited V1_FY_08 Very High Volume 2,000< 1 High Volume 2,000-1,000 2 Low Volume 1, Very Low Volume <
37 Table: 4.19 Indian pharmaceutical companies having turnover in Rs. crores for the Financial Year Sr.No. Title Turnover Num 1 Ranbaxy Laboratories 7, Cipla Limited 4, GlaxoSmithKline (India) Limited 1, Piramal Healthcare Limited 3, Zydus Cadila Limited 2, Sun Pharmaceutical Industries Limited 4, Pfizer (India) Limited 1, Alkem Laboratories Limited 1, Abbott (India) Limited 1, Lupin Laboratories Limited 3, Dr. Reddy s Laboratories Limited 6, Aristo Pharma Limited Sanofi Aventis (India) Limited Alembic Limited 1, Novartis (India) Limited Mankind Pharma Limited 1, Torrent Pharmaceuticals Limited 1, Intas Pharmaceuticals limited 1, Wockhardt Limited 3, Micro Labs Limited Emcure Pharmaceuticals Limited 1, FDC Limited Unichem Laboratories Limited Macleods Pharmaceuticals Limited USV Limited 1, Ipca Laboratories Limited 1, Glenmark Pharmaceuticals Limited 2, Cadila Pharmaceuticals Limited Elder Pharmaceuticals Limited Merck (India) Limited V1_FY_09 Very High Volume 2,000< 1 High Volume 2,000-1,000 2 Low Volume 1, Very Low Volume <
38 Table: 4.20 Indian pharmaceutical companies invested in Research & Development in Rs. crores in the Financial Year Sr. No. Title Details Num 1 Ranbaxy Laboratories Cipla Limited GlaxoSmithKline (India) Limited Piramal Healthcare Limited Zydus Cadila Limited Sun Pharmaceutical Industries Limited Pfizer (India) Limited Alkem Laboratories Limited Abbott (India) Limited Lupin Laboratories Limited Dr. Reddy s Laboratories Limited Aristo Pharma Limited Sanofi Aventis (India) Limited Alembic Limited Novartis (India) Limited Mankind Pharma Limited Torrent Pharmaceuticals Limited Intas Pharmaceuticals limited Wockhardt Limited Micro Labs Limited Emcure Pharmaceuticals Limited FDC Limited Unichem Laboratories Limited Macleods Pharmaceuticals Limited USV Limited Ipca Laboratories Limited Glenmark Pharmaceuticals Limited Cadila Pharmaceuticals Limited Elder Pharmaceuticals Limited Merck (India) Limited 20 4 V2_RD_08 Very High Volume 500< 1 High Volume Low Volume Very Low Volume <
39 Fig From the Fig it is clear that, 30% of the Indian pharmaceutical companies are having a total turnover in the range of Rs.1,000-2,000 crores in the financial year of
40 Fig From the Fig it is clear that, 37% of the Indian pharmaceutical companies are having a total turnover in the range of Rs.1,000-2,000 crores in the financial year of
41 Fig From the Fig above it is clear that 16.67% of the Indian pharmaceutical companies have already invested Rs crores in Research & Development (R&D). It is clear that of late Indian pharmaceutical companies are focusing on Research & Development (R&D) and investing significantly. For any Indian pharma company to remain ahead of the value chain it must have one Research & Development (R&D) capability. This strategy alone will separate the achievers. In order to become a major global player, many of the Indian pharmaceutical biggies, are having extensive concentration over the international markets. Many of them are using various techniques for grabbing the international sector of the pharma world, due to which the domestic market gets less focus as compared with the international market. In last five years the Indian pharma market has doubled from Rs.22,500 crores (US$ 5 billion) to Rs.49,500 crores (US$ 11billion) and it is further expected to grow to Rs. 90,000 crore (US$ 20 billion) by the year Hence, it is necessary for the Indian pharma industry to strike a perfect balance between the domestic market and international market for becoming a successful player in the pharma world. 243
42 Table: 4.21 Indian pharmaceutical companies having sales turnover from domestic market in Rs. crore for the Financial Year Sr. No. Title Details Num 1 Ranbaxy Laboratories 1, Cipla Limited 1, GlaxoSmithKline (India) Limited 1, Piramal Healthcare Limited 1, Zydus Cadila Limited 1, Sun Pharmaceutical Industries Limited 1, Pfizer (India) Limited Alkem Laboratories Limited 1, Abbott (India) Limited Lupin Laboratories Limited Dr. Reddy s Laboratories Limited Aristo Pharma Limited Sanofi Aventis (India) Limited Alembic Limited Novartis (India) Limited Mankind Pharma Limited Torrent Pharmaceuticals Limited Intas Pharmaceuticals limited Wockhardt Limited Micro Labs Limited Emcure Pharmaceuticals Limited FDC Limited Unichem Laboratories Limited Macleods Pharmaceuticals Limited USV Limited Ipca Laboratories Limited Glenmark Pharmaceuticals Limited Cadila Pharmaceuticals Limited Elder Pharmaceuticals Limited Merck (India) Limited V1_DOM_08 Very High Volume 1,500< 1 High Volume 1,500-1,000 2 Low Volume 1, Very Low Volume >
43 Table: 4.22 Indian pharmaceutical companies having sales turnover from Domestic market in Rs. crores for the Financial Year Sr. No Title Details Num 1 Ranbaxy Laboratories 1, Cipla Limited 1, GlaxoSmithKline (India) Limited 1, Piramal Healthcare Limited 1, Zydus Cadila Limited 1, Sun Pharmaceutical Industries Limited 1, Pfizer (India) Limited 1, Alkem Laboratories Limited 1, Abbott (India) Limited Lupin Laboratories Limited Dr. Reddy s Laboratories Limited Aristo Pharma Limited Sanofi Aventis (India) Limited Alembic Limited Novartis (India) Limited Mankind Pharma Limited Torrent Pharmaceuticals Limited Intas Pharmaceuticals limited Wockhardt Limited Micro Labs Limited Emcure Pharmaceuticals Limited FDC Limited Unichem Laboratories Limited Macleods Pharmaceuticals Limited USV Limited Ipca Laboratories Limited Glenmark Pharmaceuticals Limited Cadila Pharmaceuticals Limited Elder Pharmaceuticals Limited Merck (India) Limited V1_INT_08 Very High Volume 1,500< 1 High Volume 1,500-1,000 2 Low Volume 1, Very Low Volume >
44 Fig From the Fig it is clear that 23.34% of the Indian pharmaceutical companies are having a sales turnover in the range of Rs.500-1,000 crores only from the domestic market sector. 246
45 Fig From the data it is clear that Indian pharmaceutical companies are focusing on international business but as domestic market is also expanding there is shift in attention towards domestic market. In order to become a global player, the Indian pharmaceutical companies need to have balanced approach. 247
46 Table: 4.23 Indian pharmaceutical companies having strategy for collaboration with multinational companies. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited Yes 1 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited Yes 1 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited Yes 1 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited Yes 1 30 Merck (India) Limited No 2 Yes 1 and No
47 Table: 4.24 Indian pharmaceutical companies having strategy for contract research. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited Yes 1 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
48 Table: 4.25 Indian pharmaceutical companies having strategy for joint venture. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited Yes 1 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited Yes 1 23 Unichem Laboratories Limited Yes 1 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited Yes 1 30 Merck (India) Limited No 2 Yes 1 and No
49 Table: 4.26 Indian pharmaceutical companies having strategy for clinical research. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
50 Table: 4.27 Indian pharmaceutical companies having strategy for alternative medicines in Herbal. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited Yes 1 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited No 2 7 Pfizer (India) Limited Yes 1 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited Yes 1 14 Alembic Limited No 2 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited No 2 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited No 2 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited No 2 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
51 Table: 4.28 Indian pharmaceutical companies having strategy for alternative medicines in Ayurvedic. Sr. No Title Details Num 1 Ranbaxy Laboratories No 2 2 Cipla Limited No 2 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited No 2 5 Zydus Cadila Limited No 2 6 Sun Pharmaceutical Industries Limited No 2 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited No 2 11 Dr. Reddy s Laboratories Limited No 2 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited No 2 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited No 2 26 Ipca Laboratories Limited Yes` 1 27 Glenmark Pharmaceuticals Limited No 2 28 Cadila Pharmaceuticals Limited No 2 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
52 Table: 4.29 Indian pharmaceutical companies having strategy for alternative medicines in Biotech. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited Yes 1 3 GlaxoSmithKline (India) Limited Yes 1 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited Yes 1 8 Alkem Laboratories Limited Yes 1 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited Yes 1 14 Alembic Limited No 2 15 Novartis (India) Limited Yes 1 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited Yes 1 19 Wockhardt Limited Yes 1 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited Yes 1 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited Yes 1 26 Ipca Laboratories Limited Yes 1 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited Yes 1 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited Yes 1 Yes 1 and No
53 Table: 4.30 Indian pharmaceutical companies having strategy for work on drug discovery. Sr. No Title Details Num 1 Ranbaxy Laboratories Yes 1 2 Cipla Limited No 2 3 GlaxoSmithKline (India) Limited No 2 4 Piramal Healthcare Limited Yes 1 5 Zydus Cadila Limited Yes 1 6 Sun Pharmaceutical Industries Limited Yes 1 7 Pfizer (India) Limited No 2 8 Alkem Laboratories Limited No 2 9 Abbott (India) Limited No 2 10 Lupin Laboratories Limited Yes 1 11 Dr. Reddy s Laboratories Limited Yes 1 12 Aristo Pharma Limited No 2 13 Sanofi Aventis (India) Limited No 2 14 Alembic Limited No 2 15 Novartis (India) Limited No 2 16 Mankind Pharma Limited No 2 17 Torrent Pharmaceuticals Limited No 2 18 Intas Pharmaceuticals limited No 2 19 Wockhardt Limited No 2 20 Micro Labs Limited No 2 21 Emcure Pharmaceuticals Limited No 2 22 FDC Limited No 2 23 Unichem Laboratories Limited No 2 24 Macleods Pharmaceuticals Limited No 2 25 USV Limited No 2 26 Ipca Laboratories Limited No 2 27 Glenmark Pharmaceuticals Limited Yes 1 28 Cadila Pharmaceuticals Limited No 2 29 Elder Pharmaceuticals Limited No 2 30 Merck (India) Limited No 2 Yes 1 and No
54 Fig It is clear from the Fig presented here that, 67% of the Indian pharma industries have collaborated with multinational companies. 256
55 Fig From the Fig it is clear that, 53% of the Indian pharmaceutical companies have gone for contract research. Pharmaceutical companies like Piramal Healthcare and Dr. Reddy s Laboratories follow a strategy for contract research. 257
56 Fig From the Fig it is clear that, 63% of the Indian pharmaceutical companies strategically have gone for joint ventures. 258
57 Fig From the Fig it is clear that, 50% of the Indian pharmaceutical companies strategically have gone for clinical research activities. 259
58 Fig From the Fig it is clear that, 43% of the Indian pharmaceutical companies strategically focus on manufacturing herbal medicines as a part of the alternative medicines segment. 260
59 Fig From the Fig it is clear that, 30% of the Indian pharmaceutical companies strategically focus on New Drug Discovery (NDD) as a part of the alternative medicines segment. 261
60 Fig From the Fig it is clear that, 7% of the Indian pharmaceutical companies strategically focus on manufacturing ayurvedic medicines as a part of the alternative medicines segment. 262
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
More informationAStoryofSunPharmaceuticalsLaboratoriesGoingGlobal
Global Journal of HUMANSOCIAL SCIENCE: E Economics Volume 18 Issue 4 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 2249460x & Print
More informationREGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationUN Panel Discussion Millennium Development Goals. Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010
UN Panel Discussion Millennium Development Goals Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010 1 A role for everyone. North Large branded companies Strong engine of innovation Almost
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
More informationA study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL
More informationORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
More informationFree Trial Future Generics Database
API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationFor personal use only
AusCann Makes Major Progress Towards Production of Cannabinoid Medicines During FY18 Highlights Undertook comprehensive pharmaceutical development project to create an optimal dosage form cannabinoid medicine
More informationTODAY LETTER DATED
TODAY LETTER DATED 26.06.2018 GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT.. 18670 PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY
More informationMinimumum Price (Rs.) 3.30 Maximum Price (Rs.) 4.57 Average of all considered (Rs.) 3.73 Retail Price (Rs.) 4.33
Computataion of Retail Price based on Jan.-2016 Data under Para 4 of DPCO 2013 Cholecalciferol 800 IU Drops of M/s Raptakos, Brett & Co.Ltd. Number of Companies cosisting of Market Share of 1% & Above
More informationGlobal Nutraceuticals Market
Published on NOVONOUS (https://www.novonous.com) Home > Global Nutraceuticals Market 2016-2020 Global Nutraceuticals Market 2016-2020 Publication ID: NOV1016004 Publication Date: October 14, 2016 Pages:
More informationChina Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 11.04.2017 BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S ZUVENTUS HEALTHCARE LTD 6981 APPROVAL M/S TECHINVENTION LIFE SCIENCES 1208 CLARIFICATION M/S CADILA PHARMACEUTICALS LTD
More informationDataset : PharmaTrac MAT MAY PharmaTrac Overview MAY 18
PharmaTrac Overview MAY 18 8434 8956 9655 10422 8112 8917 9549 8258 8921 9406 8668 9630 9381 8662 8373 8999 9013 9796 10413 8742 9315 10050 8458 9180 8601 9092 9767 8364 9145 10583 10173 10387 10217 10476
More informationLaurus Labs Ltd (Laurus) -API leadership & R&D to drive growth
Laurus Labs Ltd (Laurus) -API leadership & R&D to drive growth 1 April 2018 Laurus Labs Ltd (Laurus) 31-03-2018 Recommendation : Buy CMP : Rs 503.00 Target : NA % Allocation : 5% Sector : Pharmaceuticals
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationNon Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018
Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationWelcome to Galenicum! APRIL, 2013
Welcome to Galenicum! APRIL, 2013 Our corporate image comes from the sunrise. Night represents disease, daylight means health and the sunrise stands for overcoming GALENICUM CORPORATE PRESENTATION 3 Who
More informationFirst and foremost we have the world s largest privately funded biomedical research group investing about $8 billion in 2008.
Rich Bagger s Talking Points for ECOSOC (Audience acknowledgement) Was asked to tackle the question: What are innovative ways that corporations can deploy their core competencies and strengths in the fight
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS
More informationSUBMISSION TGA CONSULTATION: INCENTIVES FOR INNOVATION PROTECTION MECHANISMS FOR EVIDENCE-BASED, PRE-ASSESSED COMPLEMENTARY MEDICINES JUNE 2018
SUBMISSION TGA CONSULTATION: INCENTIVES FOR INNOVATION PROTECTION MECHANISMS FOR EVIDENCE-BASED, PRE-ASSESSED COMPLEMENTARY MEDICINES JUNE 2018 The science of integrative medicine INTRODUCTION The Expert
More information### About Bharat Biotech
Press Release Bharat Biotech Bharat Biotech Launches Typbar-TCV, world s first clinically proven typhoid conjugate vaccine for infants 6 months & older and Adults The new vaccine brings hope to millions
More informationVascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
More informationCreating Lasting Value
Creating Lasting Value Investor Presentation May 2018 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein, statements
More informationInfluenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
More informationVaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationChina Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
More informationGlobal Market Analysis of Herbal Drug Formulations Joshi Nirali B 1 * and M. B. Shankar 2
REVIEW ARTICLE www.ijapc.com e-issn 2350-0204 Global Market Analysis of Herbal Drug Formulations Joshi Nirali B 1 * and M. B. Shankar 2 1 Shri Jagdish Prasad Jhabarmal Tibrewala University, Vidyanagari,
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCreating Lasting Value
Creating Lasting Value Investor Presentation Sept 2017 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein, statements
More informationHIGH CLINICAL ACCEPTANCE OF METVIX PDT
HIGH CLINICAL ACCEPTANCE OF METVIX PDT PhotoCure ASA Second Quarter Report 2002 Highlights: Marketing of Metvix PDT in Europe Progressing as Planned Positive Phase III Clinical Results in the Treatment
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCreating Lasting Value
Creating Lasting Value Investor Presentation February 2018 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein,
More informationCreating Lasting Value
Creating Lasting Value Investor Presentation November 2018 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein,
More information1 CHAPTER 1- INTRODUCTION
1 CHAPTER 1- INTRODUCTION The author is an Indian consumer studying IMBA at Siam University in Thailand. He came to Thailand to study MBA because he wanted to learn in International environment and also
More informationInformation for Vermont Prescribers of Prescription Drugs Long Form
Information for Vermont Prescribers of Prescription Drugs Long Form Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) Capsules The prices listed below are Average Wholesale
More informationNew Delhi, the 18 th December, 2017 ORDER
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationEXECUTIVE UPDATE: JUNE 2018
EXECUTIVE UPDATE: JUNE 2018 We are heading into a new financial year after 12 months of significant progress that has seen increased uptake of our technology in China and other established markets. Pleasingly,
More informationGlobal Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
More informationMARKET TREND ANALYSIS OF SILDENAFIL BRAND PERFORMANCE IN INDIAN MARKET
IJER Serials Publications 12(2), 2015: 525-529 ISSN: 0972-9380 MARKET TREND ANALYSIS OF SILDENAFIL BRAND PERFORMANCE IN INDIAN MARKET Abstract: Sildenafil being launched in pre-patent period, Indian companies
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 04.12.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. VIRCHOW BIOTECH PVT LTD - QUERY 2. M/S. MSN LABORATORIES PVT - CT-NOC & BE NOC LTD (3) 3. M/S. NATCO PHARMA LTD. - BE-NOC
More informationCreating Lasting Value
Creating Lasting Value Investor Presentation April 2017 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein, statements
More informationClustered Nutrition. - Dr. R. B. Smarta
Clustered Nutrition - Dr. R. B. Smarta The nutraceutical market of India is currently estimated to be around USD 2.4bn and it is projected to grow at a CAGR of 17%. We are now nearing the end of the year
More informationReview Article ISSN: Open Access. Regulatory Aspects of Pharmaceutical Excipients in India and their Qualification to Use in Pharmaceuticals
Review Article ISSN: 2581-4559 Open Access UPI JOURNAL OF BUSINESS MANAGEMENT AND COMPUTER APPLICATIONS Journal Home Page: https://uniquepubinternational.com/upi-journals/upi-journal-ofbusiness-management-and-computer-applications-upi-jbmca/
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
More informationCreating Lasting Value
Creating Lasting Value Investor Presentation November 2018 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein,
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationFor personal use only
ASX ANNOUNCEMENT 22 NOVEMBER 2017 AGM ADDRESSES FROM THE CHAIRMAN & CEO 22 November 2017 Cann Group Limited (ASX: CAN) is pleased to provide the following addresses to be delivered by its Chairman Allan
More informationDementia in China. China Alzheimer s Project
Dementia in China Global Public Health Challenge Global Patients Estimate (Million People) 115.4 67.5 35.6 2010 2030 2050 Source: Alzheimer s Disease International Released on September 21, 2009, World
More informationSegment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage
Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,
More informationCase 1:14-cv LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023
Case 1:14-cv-00121-LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABO RA TORIES, INC., FOREST LABO RA TORIES HOLDINGS,
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 15.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD. 22073 APPROVAL
More informationDBA Design Effectiveness Awards SoloSTAR. A disposable pen injector for insulin
DBA Design Effectiveness Awards 2009 SoloSTAR A disposable pen injector for insulin Category: Sub category: Client company: Design consultancy: Product Consumer Sanofi Aventis GmbH DCA Design International
More informationLocation of HENGRUI. The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China
1 Location of HENGRUI The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China 2 Domestic Achievements No. 1 in Market Cap No. 1 in Innovation No. 1
More informationCannabis research in Oregon under Measure 91 Mowgli Holmes, May 2015
Cannabis research in Oregon under Measure 91 Mowgli Holmes, May 2015 The Cannabis industry is springing into existence essentially overnight. It is an unprecedented hybrid kind of industry - an agricultural
More informationWHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing
WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Washington, DC January 14th 16th, 2013 Session 4: Attracting Investments and Generating Revenue Theory, Practice and
More informationTABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationThe Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
More informationEducation. Current Activities
Nirali Mehta, M.Sc., M.Phil. Founder & Consultant Biostatistician Ahmedabad, Gujarat, India. M +91 9377060504 E nirali.mehta@pharma-stats.in W www.pharma-stats.in Education 1998-2001 Bachelor of Science
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationCOMPANY PROFILE. AL SHAMS Group
COMPANY PROFILE AL SHAMS Group Al Shams Pharma Scintific Bureau Shams Al-Ibdaa Drug Store Bilim Pharma Co. Al-Shams Drug Store Al-Murjan Drug Store Al-Aqsa Pharmacy & Cosmetic Al-Khadraa Pharmacy & Cosmetic
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationGeneric Medicines in Australia. Andrew McLachlan
Generic Medicines in Australia Andrew McLachlan andrewm@pharm.usyd.edu.au The aim of this presentation Overview of medicines policy and regulation in Australia Generic medicines in the Australia market
More informationInnovator in Chelated Mineral Nutrition
Leader The World & Innovator in Chelated Mineral Nutrition 2011 Albion Human Nutrition. All rights reserved. Albion Manufacturing Technologies, Ogden Utah Albion Central Warehouse, Ogden Utah Albion Corporate
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationCANCER HAS BEEN AROUND
For decades, drug companies have been spending billions of dollars and countless hours on researching and developing treatments and cures for cancer. The reason is easy to understand. Cancer is the second-leading
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationAntifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationGLOBAL NEUROSTIMULATION MARKET
GLOBAL NEUROSTIMULATION MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d
More informationNoninvasive Glucose Monitors to 2022
Noninvasive Glucose Monitors to 2022 Devices, Technologies, Players and Prospects Report Prospectus Greystone Research associates N o n i n v a s i v e G l u c o s e M o n i t o r s t o 2 0 2 2 Greystone
More informationDiabetic Retinopathy Treatment - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022) Diabetic Retinopathy Treatment - Global Market
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 03.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S LUPIN TARAPUR, MAHARASHTRA & WC 2. M/S JPN PHARMA PVT. PALGHAR, MAHARASHTRA WC 3. M/S OPTIMUS DRUGS A.P. WC VACCINE DIVISION S.
More informationCase 2:09-cv DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95. Of Counsel:
Case 2:09-cv-01302-DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza Newark, NJ 07102 (973) 286-6700 clizza@saul.com Attorneys for Plaintiff
More informationPharmaceuticals Working Group Output Recommendations. Dr Oliver Werner & Vd J Pandey Chair & Co Chair
Pharmaceuticals Working Group Output Recommendations Dr Oliver Werner & Vd J Pandey Chair & Co Chair Focus Areas Good Manufacturing Practices Pharmacopoeia Standards Issues related to establishing contact
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationDealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep
Dealdoc Licensing, development and marketing agreement for Relenza Glaxo Wellcome GlaxoSmithKline Biota Sep 04 2000 Licensing, development and marketing agreement for Relenza Glaxo Wellcome Companies:
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationUpdate from FDA Office of Regulatory Affairs
Update from FDA Office of Regulatory Affairs Ellen F. Morrison Assistant Commissioner for Medical Products and Tobacco Operations Office of Regulatory Affairs U.S. Food and Drug Administration 1 The Impact
More informationPrescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study
Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study Presented By: Scott McKibbin Special Advocate For Prescription Drugs State Of Illinois
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationCreating Lasting Value
Creating Lasting Value Investor Presentation February 2017 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein,
More information